Sasso E, Paciello R, DAuria F, Riccio G, Froechlich G, Cortese R, et al. One-step recovery of scFv clones from high-throughput sequencing-based screening of phage display libraries challenged to cells expressing native claudin-1. Biomed Res Int. 2015;2015:703213.

Article PubMed PubMed Central Google Scholar

Zambrano N, Froechlich G, Lazarevic D, Passariello M, Nicosia A, De Lorenzo C, et al. High-throughput monoclonal antibody discovery from phage libraries: challenging the current preclinical pipeline to keep the pace with the increasing mAb demand. Cancers. 2022;14:1325.

Article CAS PubMed PubMed Central Google Scholar

Esposito MV, Minopoli G, Esposito L, DArgenio V, Di Maggio F, Sasso E, et al. A functional analysis of the unclassified Pro2767Ser BRCA2 variant reveals its potential pathogenicity that acts by hampering DNA binding and homology-mediated DNA repair. Cancers. 2019;11:1454.

Article CAS PubMed PubMed Central Google Scholar

Barsi S, Szalai B. Modeling in systems biology: causal understanding before prediction? Patterns. 2021;2:100280.

Article PubMed PubMed Central Google Scholar

Chen R, Snyder M. Systems biology: personalized medicine for the future? Curr Opin Pharmacol. 2012;12:6238.

Article CAS PubMed PubMed Central Google Scholar

Passariello M, Vetrei C, Sasso E, Froechlich G, Gentile C, DAlise AM, et al. Isolation of two novel human anti-CTLA-4 mAbs with intriguing biological properties on tumor and NK cells. Cancers. 2020;12:2204.

Article CAS PubMed PubMed Central Google Scholar

Guhathakurta D, Sheikh NA, Meagher TC, Letarte S, Trager JB. Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome. Expert Rev Clin Pharmacol. 2013;6:387401.

Article CAS PubMed Google Scholar

DAlise AM, Nocchi L, Garzia I, Secl L, Infante L, Troise F, et al. Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer. Front Immunol. 2023;14:1156714.

Article PubMed PubMed Central Google Scholar

Lembo RR, Manna L, Froechlich G, Sasso E, Passariello M, De Lorenzo C. New insights on the role of anti-PD-L1 and anti-CTLA-4 mAbs on different lymphocytes subpopulations in TNBC. Cancers. 2022;14:5289.

Article CAS PubMed PubMed Central Google Scholar

Gentile C, Finizio A, Froechlich G, DAlise AM, Cotugno G, Amiranda S, et al. Generation of a retargeted oncolytic herpes virus encoding adenosine deaminase for tumor adenosine clearance. Int J Mol Sci. 2021;22:13521.

Article CAS PubMed PubMed Central Google Scholar

Froechlich G, Caiazza C, Gentile C, DAlise AM, De Lucia M, Langone F, et al. Integrity of the antiviral STING-mediated DNA sensing in tumor cells is required to sustain the immunotherapeutic efficacy of herpes simplex oncolytic virus. Cancers. 2020;12:3407.

Article CAS PubMed PubMed Central Google Scholar

Hewitt SL, Bai A, Bailey D, Ichikawa K, Zielinski J, Karp R, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs. Sci Transl Med. 2019;11:eaat9143.

Article CAS PubMed Google Scholar

Gelzo M, Scial F, Cacciapuoti S, Pinchera B, De Rosa A, Cernera G, et al. Inducible nitric oxide synthase (iNOS): why a different production in COVID-19 patients of the two waves? Viruses. 2022;14:534.

Article CAS PubMed PubMed Central Google Scholar

Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, et al. Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. Front Immunol. 2017;8:555.

Article PubMed PubMed Central Google Scholar

Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:16077.

Article PubMed Google Scholar

Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B, Campadelli-Fiume G. HSV as a platform for the generation of retargeted, armed, and reporter-expressing oncolytic viruses. Viruses. 2018;10:352.

Article PubMed PubMed Central Google Scholar

Froechlich G, Gentile C, Infante L, Caiazza C, Pagano P, Scatigna S, et al. Generation of a novel mesothelin-targeted oncolytic herpes virus and implemented strategies for manufacturing. Int J Mol Sci. 2021;22:477.

Article CAS PubMed PubMed Central Google Scholar

Sasso E, Froechlich G, Cotugno G, DAlise AM, Gentile C, Bignone V, et al. Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis. Sci Rep. 2020;10:4307.

Article CAS PubMed PubMed Central Google Scholar

Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol Ther. 2015;23:99107.

Article CAS PubMed Google Scholar

Tripodi L, Feola S, Granata I, Whalley T, Passariello M, Capasso C, et al. Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma. iScience. 2023;26:107668.

Article CAS PubMed PubMed Central Google Scholar

de Graaf JF, de Vor L, Fouchier RAM, van den Hoogen BG. Armed oncolytic viruses: a kick-start for anti-tumor immunity. Cytokine Growth Factor Rev. 2018;41:2839.

Article PubMed PubMed Central Google Scholar

Sasso E, DAlise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A. New viral vectors for infectious diseases and cancer. Semin Immunol. 2020;50:101430.

Article CAS PubMed Google Scholar

Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer. 2020;8:e001486.

Article PubMed PubMed Central Google Scholar

Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5:e1115641.

Article PubMed Google Scholar

De Lucia M, Cotugno G, Bignone V, Garzia I, Nocchi L, Langone F, et al. Retargeted and multi-cytokine-armed herpes virus is a potent cancer endovaccine for local and systemic anti-tumor treatment. Mol Ther Oncolytics. 2020;19:25364.

Article PubMed PubMed Central Google Scholar

Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity. 2019;51:54860.e544.

Article CAS PubMed PubMed Central Google Scholar

Vetrei C, Passariello M, Froechlich G, Rapuano Lembo R, Sasso E, et al. Novel combinations of human immunomodulatory mabs lacking cardiotoxic effects for therapy of TNBC. Cancers. 2021;14:121.

Article PubMed PubMed Central Google Scholar

Baruah P, Lee M, Odutoye T, Williamson P, Hyde N, Kaski JC, et al. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. Immunobiology. 2012;217:66975.

Article CAS PubMed Google Scholar

Kuss I, Donnenberg AD, Gooding W, Whiteside TL. Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck. Br J Cancer. 2003;88:22330.

Article CAS PubMed PubMed Central Google Scholar

Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, et al. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun. 2017;8:14340.

Article CAS PubMed PubMed Central Google Scholar

Ramelyte E, Tastanova A, Balzs Z, Ignatova D, Turko P, Menzel U, et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell. 2021;39:394406.e394.

Article CAS PubMed Google Scholar

Tripodi L, Sasso E, Feola S, Coluccino L, Vitale M, Leoni G, et al. Systems biology approaches for the improvement of oncolytic virus-based immunotherapies. Cancers. 2023;15:1297.

Article CAS PubMed PubMed Central Google Scholar

Froechlich G, Finizio A, Napolano A, Amiranda S, De Chiara A, Pagano P, et al. The common H232 STING allele shows impaired activities in DNA sensing, susceptibility to viral infection, and in monocyte cell function, while the HAQ variant possesses wild-type properties. Sci Rep. 2023;13:19541.

Article CAS PubMed PubMed Central Google Scholar

Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol. 2008;82:1015361.

Article CAS PubMed PubMed Central Google Scholar

Leoni V, Vannini A, Gatta V, Rambaldi J, Sanapo M, Barboni C. et al. A fully virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors. PLoS Pathog. 2018;14:e1007209.

Article PubMed PubMed Central Google Scholar

Cembrola B, Ruzza V, Troise F, Esposito ML, Sasso E, Cafaro V, et al. Rapid affinity maturation of novel anti-PD-L1 antibodies by a fast drop of the antigen concentration and FACS selection of yeast libraries. Biomed Res Int. 2019;2019:6051870.

Article PubMed PubMed Central Google Scholar

Gianni T, Leoni V, Sanapo M, Parenti F, Bressanin D, Barboni C, et al. Genotype of immunologically hot or cold tumors determines the antitumor immune response and efficacy by fully virulent retargeted oHSV. Viruses. 2021;13:1747.

Article CAS PubMed PubMed Central Google Scholar

Vannini A, Parenti F, Barboni C, Forghieri C, Leoni V, Sanapo M, et al. Efficacy of systemically administered retargeted oncolytic herpes simplex viruses-clearance and biodistribution in nave and HSV-preimmune mice. Cancer. 2023;15:4042.

Article CAS Google Scholar

Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41:52840.

Article CAS PubMed Google Scholar

Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, hrling K, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019;7:145.

Article PubMed PubMed Central Google Scholar

Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623:15766.

Article CAS PubMed PubMed Central Google Scholar

Wan PK, Fernandes RA, Seymour LW. Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent? J Immunother Cancer. 2023;11:e006518.

Article PubMed PubMed Central Google Scholar

Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, et al. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. J Immunother Cancer. 2019;7:214.

Article PubMed PubMed Central Google Scholar

Wenthe J, Eriksson E, Hellstrm AC, Moreno R, Ullenhag G, Alemany R, et al. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. J Transl Med. 2023;21:506.

Article CAS PubMed PubMed Central Google Scholar

Labani-Motlagh A, Naseri S, Wenthe J, Eriksson E, Loskog A. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. Mol Ther Oncolytics. 2021;20:50818.

Article CAS PubMed PubMed Central Google Scholar

Chon HJ, Lee WS, Yang H, Kong SJ, Lee NK, Moon ES, et al. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade. Clin Cancer Res. 2019;25:161223.

Article CAS PubMed Google Scholar

Yamashita M, Tasaki M, Murakami R, Arai Y, Nakamura T, Nakao S. Oncolytic vaccinia virus induces a novel phenotype of CD8(+) effector T cells characterized by high ICOS expression. Mol Ther Oncolytics. 2021;20:42232.

Article CAS PubMed PubMed Central Google Scholar

Boagni DA, Ravirala D, Zhang SX. Current strategies in engaging oncolytic viruses with antitumor immunity. Mol Ther Oncolytics. 2021;22:98113.

Article CAS PubMed PubMed Central Google Scholar

Sasso E, Latino D, Froechlich G, Succoio M, Passariello M, De Lorenzo C, et al. A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells. MAbs. 2018;10:7307.

Article CAS PubMed PubMed Central Google Scholar

Rusciano G, Sasso E, Capaccio A, Zambrano N, Sasso A. Revealing membrane alteration in cellsoverexpressing CA IX and EGFR by Surface-enhanced Raman Scattering. Sci Rep. 2019;9:1832.

Article PubMed PubMed Central Google Scholar

See the article here:

Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory ... - Nature.com